FI3880186T3 - PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi - Google Patents
PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi Download PDFInfo
- Publication number
- FI3880186T3 FI3880186T3 FIEP19817846.9T FI19817846T FI3880186T3 FI 3880186 T3 FI3880186 T3 FI 3880186T3 FI 19817846 T FI19817846 T FI 19817846T FI 3880186 T3 FI3880186 T3 FI 3880186T3
- Authority
- FI
- Finland
- Prior art keywords
- tumor
- pharmaceutical composition
- inhibitor
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767218P | 2018-11-14 | 2018-11-14 | |
| PCT/US2019/061212 WO2020102375A1 (en) | 2018-11-14 | 2019-11-13 | Intralesional administration of pd-1 inhibitors for treating skin cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3880186T3 true FI3880186T3 (fi) | 2024-05-30 |
Family
ID=68841191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19817846.9T FI3880186T3 (fi) | 2018-11-14 | 2019-11-13 | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12473364B2 (https=) |
| EP (2) | EP3880186B1 (https=) |
| JP (2) | JP7513604B2 (https=) |
| CN (1) | CN113038939A (https=) |
| DK (1) | DK3880186T3 (https=) |
| ES (1) | ES2980363T3 (https=) |
| FI (1) | FI3880186T3 (https=) |
| HR (1) | HRP20240825T1 (https=) |
| HU (1) | HUE067601T2 (https=) |
| LT (1) | LT3880186T (https=) |
| PL (1) | PL3880186T3 (https=) |
| PT (1) | PT3880186T (https=) |
| RS (1) | RS65627B1 (https=) |
| SI (1) | SI3880186T1 (https=) |
| SM (1) | SMT202400252T1 (https=) |
| WO (1) | WO2020102375A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| EP4313123A1 (en) * | 2021-03-23 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| KR102228296B1 (ko) | 2012-03-16 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| JP6295998B2 (ja) | 2015-05-12 | 2018-03-20 | 株式会社デンソー | 内燃機関の再始動制御装置 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| EP3402517B1 (en) | 2016-01-15 | 2025-08-20 | RFEMB Holdings, LLC | Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| WO2018106862A1 (en) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| US10166290B2 (en) | 2017-02-24 | 2019-01-01 | Max H. Cohen | Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2019
- 2019-11-13 HU HUE19817846A patent/HUE067601T2/hu unknown
- 2019-11-13 PL PL19817846.9T patent/PL3880186T3/pl unknown
- 2019-11-13 US US17/292,179 patent/US12473364B2/en active Active
- 2019-11-13 HR HRP20240825TT patent/HRP20240825T1/hr unknown
- 2019-11-13 PT PT198178469T patent/PT3880186T/pt unknown
- 2019-11-13 SM SM20240252T patent/SMT202400252T1/it unknown
- 2019-11-13 EP EP19817846.9A patent/EP3880186B1/en active Active
- 2019-11-13 RS RS20240682A patent/RS65627B1/sr unknown
- 2019-11-13 FI FIEP19817846.9T patent/FI3880186T3/fi active
- 2019-11-13 SI SI201930759T patent/SI3880186T1/sl unknown
- 2019-11-13 JP JP2021526256A patent/JP7513604B2/ja active Active
- 2019-11-13 CN CN201980074748.7A patent/CN113038939A/zh active Pending
- 2019-11-13 DK DK19817846.9T patent/DK3880186T3/da active
- 2019-11-13 WO PCT/US2019/061212 patent/WO2020102375A1/en not_active Ceased
- 2019-11-13 ES ES19817846T patent/ES2980363T3/es active Active
- 2019-11-13 EP EP24158793.0A patent/EP4382168A3/en active Pending
- 2019-11-13 LT LTEPPCT/US2019/061212T patent/LT3880186T/lt unknown
-
2024
- 2024-06-26 JP JP2024102591A patent/JP2024123216A/ja active Pending
-
2025
- 2025-10-24 US US19/368,062 patent/US20260042841A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4382168A3 (en) | 2024-08-28 |
| US12473364B2 (en) | 2025-11-18 |
| WO2020102375A1 (en) | 2020-05-22 |
| US20210388091A1 (en) | 2021-12-16 |
| JP2022513029A (ja) | 2022-02-07 |
| EP3880186A1 (en) | 2021-09-22 |
| US20260042841A1 (en) | 2026-02-12 |
| EP4382168A2 (en) | 2024-06-12 |
| JP2024123216A (ja) | 2024-09-10 |
| DK3880186T3 (da) | 2024-06-03 |
| SMT202400252T1 (it) | 2024-07-09 |
| PL3880186T3 (pl) | 2024-07-22 |
| CN113038939A (zh) | 2021-06-25 |
| SI3880186T1 (sl) | 2024-07-31 |
| HRP20240825T1 (hr) | 2024-09-27 |
| JP7513604B2 (ja) | 2024-07-09 |
| RS65627B1 (sr) | 2024-07-31 |
| LT3880186T (lt) | 2024-06-10 |
| PT3880186T (pt) | 2024-05-28 |
| HUE067601T2 (hu) | 2024-10-28 |
| EP3880186B1 (en) | 2024-04-03 |
| ES2980363T3 (es) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP2019515008A5 (https=) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| HRP20230236T1 (hr) | Postupci liječenja raka kože primjenom inhibitora pd-1 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2020508317A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2021528423A5 (https=) | ||
| JP2019519499A5 (https=) | ||
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| IL308805A (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| IL316404A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
| JP2019524820A5 (https=) | ||
| JPWO2019246356A5 (https=) | ||
| Havnaer et al. | Systemic therapies in psoriasis: An update on newly approved and pipeline biologics and oral treatments | |
| JP2021533142A5 (https=) | ||
| JPWO2021224499A5 (https=) | ||
| JP2020535180A5 (https=) | ||
| JPWO2020102375A5 (https=) | ||
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи |